ストックスクリーナーアプリを入手
5.07
5.41%
0.26
アフターアワーズ：
5.04
-0.03
-0.59%
前日終値:
$4.81
開ける：
$4.998
24時間の取引高:
2.81M
Relative Volume:
0.95
時価総額：
$859.04M
収益：
$101.21M
当期純損益:
$-569.00K
株価収益率:
-253.50
EPS:
-0.02
ネットキャッシュフロー:
$-56.88M
1週間 パフォーマンス:
-12.28%
1か月 パフォーマンス:
-10.58%
6か月 パフォーマンス:
+141.43%
1年 パフォーマンス:
+676.65%
1日の値動き範囲:
$4.8201
$5.12
1週間の範囲:
$4.80
$5.74
52週間の値動き範囲:
$0.40
$6.35
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
名前
Cytomx Therapeutics Inc
セクター
電話
650.515.3185
住所
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Compare CTMX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
5.07 | 814.98M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-20 | 開始されました | Guggenheim | Buy |
| 2025-09-22 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-09-17 | 再開されました | Barclays | Overweight |
| 2025-07-31 | 開始されました | Oppenheimer | Outperform |
| 2025-05-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | 再開されました | Piper Sandler | Overweight |
| 2024-05-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | アップグレード | Wedbush | Neutral → Outperform |
| 2024-05-06 | アップグレード | Jefferies | Hold → Buy |
| 2024-04-22 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-11-14 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-07 | ダウングレード | Mizuho | Buy → Neutral |
| 2022-07-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2022-01-18 | アップグレード | Barclays | Underweight → Overweight |
| 2021-11-15 | 開始されました | BTIG Research | Buy |
| 2021-05-28 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2021-03-29 | 開始されました | JP Morgan | Overweight |
| 2021-03-23 | アップグレード | Jefferies | Hold → Buy |
| 2020-09-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-06-01 | ダウングレード | Jefferies | Buy → Hold |
| 2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-24 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-04 | 開始されました | Barclays | Equal Weight |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
| 2019-11-11 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-06-13 | 開始されました | Mizuho | Buy |
| 2019-05-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2019-03-11 | 開始されました | Barclays | Overweight |
| 2018-11-26 | 開始されました | Piper Jaffray | Overweight |
| 2018-10-15 | 開始されました | Goldman | Neutral |
| 2018-09-13 | 開始されました | H.C. Wainwright | Buy |
| 2018-06-01 | 開始されました | SunTrust | Buy |
| 2018-01-05 | 開始されました | Citigroup | Buy |
| 2017-09-08 | 開始されました | Wedbush | Outperform |
| 2017-03-27 | 開始されました | H.C. Wainwright | Buy |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2017-01-03 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2015-11-02 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Cytomx Therapeutics Inc (CTMX) 最新ニュース
Market Fear: Whats the profit margin of CytomX Therapeutics IncWeekly Stock Recap & Precise Swing Trade Alerts - baoquankhu1.vn
CytomX Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 16, 2026 - Bitget
Kynam Capital files 5.29% stake in CytomX (NASDAQ: CTMX) - Stock Titan
CytomX Therapeutics Target of Unusually High Options Trading (NASDAQ:CTMX) - MarketBeat
CytomX Therapeutics, Inc. to Announce Full Year 2025 Financial Results on March 16, 2026 - Quiver Quantitative
Biotech CytomX sets Mar. 16 call on 2025 financial results - Stock Titan
CTMX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
CytomX Therapeutics Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
CytomX Therapeutics, Inc. (CTMX): Investor Outlook Reveals 55.71% Potential Upside - DirectorsTalk Interviews
CTMXCytomx Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Earnings Recap: Is CytomX Therapeutics Inc a good ESG investment2025 Stock Rankings & Proven Capital Preservation Methods - baoquankhu1.vn
CytomX Therapeutics (CTMX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Is CytomX Therapeutics Inc stock showing strong momentumJuly 2025 Sector Moves & Low Risk High Reward Ideas - baoquankhu1.vn
Will CytomX Therapeutics Inc. (6C1) stock rise with strong economyWeekly Trend Recap & Smart Swing Trading Techniques - mfd.ru
Unmasking CytomXA Pioneer In Masked Therapeutics - RTTNews
Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating - Finviz
Tang Capital reports 0% CytomX (CTMX) stake in latest 13G/A filing - Stock Titan
Is CytomX Therapeutics Inc. stock positioned well for digital economyDip Buying & Real-Time Buy Signal Notifications - mfd.ru
CTMX Should I Buy - Intellectia AI
Is CytomX Therapeutics Inc. (6C1) stock a fit for income portfolios2025 Buyback Activity & Expert Curated Trade Setups - mfd.ru
Will CytomX Therapeutics Inc. stock benefit from infrastructure spendingJuly 2025 Big Picture & Entry Point Strategy Guides - mfd.ru
Can CytomX Therapeutics Inc. disrupt its industryEarnings Recap Summary & Fast Entry Momentum Alerts - mfd.ru
Market Trends: What hedge funds are buying CytomX Therapeutics Inc2025 Fundamental Recap & AI Enhanced Trading Signals - baoquankhu1.vn
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Quarterly Recap: Is CytomX Therapeutics Inc benefiting from interest rate changesMarket Sentiment Report & Technical Pattern Based Buy Signals - baoquankhu1.vn
CytomX Therapeutics, Inc. (CTMX) Investor Outlook: A Biotech Pioneer with a 61.87% Potential Upside - DirectorsTalk Interviews
CytomX Therapeutics Conference: CFO Highlights Varseta-M CRC Response Data, Next Catalysts - MarketBeat
FMR LLC's Strategic Acquisition of CytomX Therapeutics Inc Shares - GuruFocus
CytomX at Guggenheim Summit: Promising CRC Treatment Path By Investing.com - Investing.com Canada
Stock Recap: Is CytomX Therapeutics Inc benefiting from interest rate changes2025 Institutional Moves & Capital Protection Trade Alerts - baoquankhu1.vn
How New Analyst Assumptions Are Rewriting The Story For CytomX Therapeutics (CTMX) - Yahoo Finance
CTMX: Masked ADC shows 28% response in late-line CRC; registrational study planned by 2027 - TradingView
Rally Mode: Can CytomX Therapeutics Inc navigate macro headwindsJuly 2025 PreEarnings & High Yield Equity Trading Tips - baoquankhu1.vn
CytomX Therapeutics2026 Funding Rounds & List of Investors - Tracxn
Oppenheimer Remains a Buy on CytomX Therapeutics (CTMX) - The Globe and Mail
Analysts bullish ahead of colorectal cancer readout for CytomX Therapeutics, Inc. (CTMX) - MSN
CytomX Therapeutics, Inc. (CTMX) Investor Outlook: Exploring a 58.73% Potential Upside Amid Innovative Oncology Developments - DirectorsTalk Interviews
Analysis Recap: Whats the profit margin of CytomX Therapeutics IncWeekly Trend Summary & Smart Investment Allocation Tips - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Will CytomX Therapeutics Inc. (6C1) stock outperform foreign stocksJuly 2025 News Drivers & AI Enhanced Trade Execution Alerts - mfd.ru
CytomX Therapeutics (CTMX) Price Target Increased by 20.20% to 8.67 - Nasdaq
Cantor Fitzgerald Raises Price Target for CytomX Therapeutics (C - GuruFocus
Cantor Fitzgerald Raises CytomX Therapeutics (NASDAQ:CTMX) Price Target to $10.00 - MarketBeat
CTMX: Barclays Analyst Raises Price Target to $10.00 | CTMX Stock News - GuruFocus
CytomX Therapeutics to Present at Upcoming February Conferences - 富途牛牛
CytomX Therapeutics price target raised to $10 from $8 at Barclays - TipRanks
A Look At CytomX Therapeutics (CTMX) Valuation After Optimistic Analyst Target Hikes On Phase 1 Cancer Data - Sahm
CytomX Therapeutics stock hits 52-week high at 6.16 USD By Investing.com - Investing.com Nigeria
CytomX Therapeutics (NASDAQ:CTMX) Hits New 1-Year HighHere's Why - MarketBeat
CytomX Therapeutics stock hits 52-week high at 6.16 USD - Investing.com
CytomX Therapeutics (CTMX) Is Up 14.0% After Early Probody Colorectal Cancer Data Are Welcomed By Analysts – Has The Bull Case Changed? - Yahoo Finance
Cytomx Therapeutics Inc (CTMX) 財務データ
収益
当期純利益
現金流量
EPS
0.11%
6.00%
大文字化:
|
ボリューム (24 時間):